HOME >> BIOLOGY >> NEWS
JCI table of contents November, 2005

EDITOR'S PICK
A NOVEL MECHANISM OF ACTION FOR LEAD ANTI-TUMOR AGENT

Anti-angiogenic agents have been successful in the clinic for blocking the growth of solid tumors. However, these agents used in combination with chemotherapy have improved the survival of patients with cancers by only several months. Therefore, identification of unrecognized angiogenic pathways that selectively support tumor neo-vessel assembly will increase the efficacy of anti-angiogenic or anti-vascular therapy.

The prototypical vascular targeting agent combretastatin A4 phosphate (CA4P) exerts its anti-angiogenic effect by targeting unstable budding tumor neo-vessels. CA4P is currently being studied in clinical trials in oncology.

In a paper appearing online on October 6 in advance of print publication of the November issue of the Journal of Clinical Investigation, Shahin Rafii and colleagues from Cornell University provide important mechanistic data demonstrating how CA4P has anti-tumor and anti-angiogenic activity.

The authors find that CA4P selectively targets endothelial cells (flat-shaped cells that make up the inside of blood vessels) but not smooth muscle cells (cells which surround most blood vessels), and induces regression of unstable, newly formed vessels by disruption of Vascular Endothelial-cadherin (VE-cadherin) signaling. VE-cadherin is a protein found at the junctions of overlapping regions of endothelial cells and plays a key role in many aspects of vascular function including, endothelial cell survival, cell migration, cell proliferation and assembly into vessel-like structures.

Dissecting the mechanism whereby CA4P exerts its anti-vascular effect will open up new avenues of research to selectively target tumor neo-vessels and increase the therapeutic window of anti-angiogenic agents.

TITLE: Combretastatin A4 phosphate disrupts tumor vasculature and growth by interfering with vascular endothelial-cadherin
'"/>

Contact: Stacie Bloom
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
6-Oct-2005


Page: 1 2 3 4 5 6

Related biology news :

1. Antioxidant overload may underlie a heritable human disease
2. JCI table of contents: Aug. 9, 2007
3. JCI table of contents: August 1, 2007
4. US Department of Defense awards $1.6 million for implantable biochip research
5. More fish oil, less vegetable oil, better for your health
6. JCI table of contents -- July 26, 2007
7. JCI table of contents: July 19, 2007
8. JCI table of contents: July 12, 2007
9. JCI table of contents: June 21, 2007
10. JCI table of contents: June 14, 2007
11. Food safety begins as vegetables grow

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/31/2020)... ... 30, 2020 , ... BioFactura, Inc. today announced a $1 ... Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) of the Department of Defense ... highly efficient mammalian cell culture-based bioprocess suitable to meet surge requirement needs for ...
(Date:7/10/2020)... ... July 08, 2020 , ... Overcoming ... Therapy Regulation, An FDAnews Webinar, Wednesday, July 22, 2020 • 1:30 p.m.-3:00 p.m. ... what is the most effective way to complete one? Will the study comply ...
(Date:7/1/2020)... ... July 01, 2020 , ... Catalent, a global leader ... Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture of Japan. ... in Kakegawa, the new 60,000-square-foot facility will provide customers with flexible clinical supply ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... 2020 , ... dicentra , a leading Contract Research ... is pleased to announce that Charles Galea has joined its clinical trials division ... an accomplished and results-driven sales executive with over 10 years of expertise in ...
(Date:7/10/2020)... LEXINGTON, Mass. (PRWEB) , ... July 09, 2020 ... ... novel approaches to cell therapy, today announced the hiring of Allen R. Nissenson, ... executive team and oversee the clinical development of Sentien’s lead product, SBI-101. ...
(Date:7/1/2020)... ... 29, 2020 , ... The Interlocal Purchasing System (TIPS), a ... recently named BioFit Engineered Products an Awarded Vendor. Awarded Vendor status ... cafeteria tables, book trucks and carts at discounted pricing without the delay and ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... photodynamic therapy for treating cancer, today announced the company has entered a license ... The agreement provides Lumeda globally exclusive rights to Roswell Park intellectual property ...
Breaking Biology Technology:
Cached News: